Karyopharm Therapeutics Inc. (KPTI) Stock

Karyopharm Therapeutics Inc. (KPTI) is a Healthcare stock trading at $1.97 (as of 2026-08-21), with a market capitalization of $44.57M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Understand Karyopharm Therapeutics Inc.: how it makes money

Karyopharm Therapeutics develops and commercializes cancer and other disease treatments that target nuclear export (SINE compounds, including XPOVIO), and it makes money primarily from product sales of Expovio and also from license and other revenue.

Near-term results depend heavily on how much Expovio gross sales convert into net product revenue, because gross-to-net discounts and return reserve impacts directly reduce the revenue the company reports from product sales.

Revenue by segment (latest quarter)
CPG-1018 Adj$0.1B
Expovio Net$0.0B
License Other$0.0B

Business quality (Weak): Commercial revenue exists (Expovio net product revenue and license and other revenue), but profitability is weak (operating margin of -76.3%), so investors must focus on net sales conversion and progress in key clinical programs.

Bull case

  • Net sales and mix are measurable: The company reports Expovio Net Product Revenue (0.02 USD_B) and also tracks sales financing effects such as gross-to-net discounts.
  • Clinical program has reported response rates and active enrollment: SENTRY Trial enrollment is shown as approximately 80.0 percent, and reported Spleen Volume Response Rates include 67.0 percent at 25 percent or more reduction and 33.0 percent at 35 percent or more reduction.

Bear case

  • Profitability is very negative: Operating margin is -76.3 for the period ending 2026-03-31, indicating substantial operating losses.
  • Net revenue can be pressured by discounts and returns: Gross-to-Net Discounts are shown as 21.8 percent, a separate Gross-to-Net Discount for Expovio is shown as 31.0 percent, and there is also a line item noting that net product revenue was adversely impacted by atypical returns via an increase in product return reserve.
  • Trial enrollment is not shown as fully complete: SENTRY Trial Enrollment Completion Percentage is shown as approximately 80.0 percent, so execution timing risk remains.
Valuation — source: SEC EDGAR (first-party)
Price$1.97
Market Cap$44.57M
Price / Sales0.30
FCF Yield-272.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$146.07M
Net Margin-134.2%
Revenue Growth (YoY)-11.9%
EPS Growth (YoY)-46.3%
Financial Health — source: SEC EDGAR
Altman Z-Score-23.96 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderContext Capital Management, LLC ($463.64M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORichard A. Paulson
Employees279
CountryUS
IPO Date2013-11-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Hyperion DeFi, Inc. (HYPD)
  • Tenax Therapeutics, Inc. (TENX)
  • Grace Therapeutics, Inc. (GRCE)
  • FILANA THERAPEUTICS, INC. (FLNA)
  • Seres Therapeutics, Inc. (MCRB)
  • Silo Pharma, Inc. (SILO)
  • Veru Inc. (VERU)
  • PDS Biotechnology Corporation (PDSB)
KPTI earnings history · KPTI institutional & insider holders · KPTI KPIs & operating metrics · KPTI financials · KPTI investor presentations & press releases · KPTI SEC filings · KPTI peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.